benztropine and Movement-Disorders

benztropine has been researched along with Movement-Disorders* in 27 studies

Reviews

3 review(s) available for benztropine and Movement-Disorders

ArticleYear
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
    Confinia neurologica, 1974, Volume: 36, Issue:4-6

    Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Olivary Nucleus; Parkinson Disease; Putamen; Rats; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Tremor

1974
Side effects of depot fluphenazines.
    Advances in biochemical psychopharmacology, 1974, Volume: 9, Issue:0

    Topics: Agranulocytosis; Barbiturates; Basal Ganglia Diseases; Benztropine; Biperiden; Delayed-Action Preparations; Depression; Diazepam; Drug Interactions; Eye Manifestations; Fatty Acids; Female; Fluphenazine; Humans; Jaundice; Male; Mental Disorders; Movement Disorders; Parkinson Disease, Secondary; Schizophrenia; Seizures; Skin Manifestations

1974
Drug-induced extrapyramidal disorders.
    Research publications - Association for Research in Nervous and Mental Disease, 1972, Volume: 50

    Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Benztropine; Dihydroxyphenylalanine; Dopamine; Drug-Related Side Effects and Adverse Reactions; Extrapyramidal Tracts; Haloperidol; Humans; Methyltyrosines; Movement Disorders; Phenothiazines; Phenylacetates; Probenecid; Reserpine; Synaptic Transmission; Tetrabenazine; Tranquilizing Agents; Trihexyphenidyl

1972

Trials

5 trial(s) available for benztropine and Movement-Disorders

ArticleYear
A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
    Current therapeutic research, clinical and experimental, 1973, Volume: 15, Issue:8

    Topics: Adult; Amantadine; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebos

1973
Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
    Archives of general psychiatry, 1972, Volume: 26, Issue:4

    Topics: 1-Propanol; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Biperiden; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Evaluation Studies as Topic; Humans; Male; Middle Aged; Movement Disorders; Parasympatholytics; Piperidines; Procyclidine; Pyrrolidines; Schizophrenia; Tranquilizing Agents; Trihexyphenidyl; Tropanes

1972
Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu.
    The Journal of nervous and mental disease, 1972, Volume: 155, Issue:4

    Topics: Antiparkinson Agents; Anxiety; Attitude of Health Personnel; Benztropine; Clinical Trials as Topic; Evaluation Studies as Topic; Haloperidol; Humans; Milieu Therapy; Movement Disorders; Neurotic Disorders; Personality Inventory; Schizophrenia

1972
Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Current therapeutic research, clinical and experimental, 1972, Volume: 14, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Humans; Middle Aged; Movement Disorders; Neurologic Manifestations; Parasympatholytics; Psychiatric Status Rating Scales; Schizophrenia; Time Factors; Tranquilizing Agents; Tropanes

1972
A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
    Acta psychiatrica Scandinavica, 1971, Volume: 47, Issue:4

    Topics: Administration, Oral; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Benzyl Compounds; Clinical Trials as Topic; Delayed-Action Preparations; Evaluation Studies as Topic; Haloperidol; Humans; Injections, Intramuscular; Intraocular Pressure; Male; Middle Aged; Movement Disorders; Parasympatholytics; Piperidines; Piperidones; Placebos; Psychotic Disorders; Tropanes

1971

Other Studies

19 other study(ies) available for benztropine and Movement-Disorders

ArticleYear
Investigating Real-World Benztropine Usage Patterns in Movement Disorders: Claims Analysis and Health Care Provider Survey Results.
    The primary care companion for CNS disorders, 2023, Aug-29, Volume: 25, Issue:4

    Topics: Benztropine; Health Personnel; Humans; Insurance Claim Review; Movement Disorders; Retrospective Studies; Tardive Dyskinesia

2023
Cyproheptadine in movement disorders.
    The American journal of psychiatry, 1989, Volume: 146, Issue:4

    Topics: Benztropine; Cyproheptadine; Humans; Male; Movement Disorders

1989
Prolonged metoclopramide-induced dyskinetic reaction.
    Neurology, 1984, Volume: 34, Issue:2

    Metoclopramide is an effective non-phenothiazine antiemetic that acts, in part, by blockade of the dopamine receptors. The extrapyramidal complications of metoclopramide are similar to those of the phenothiazines. A patient is reported who developed a metoclopramide-induced acute dystonic reaction lasting 53 days. Acute and chronic treatment with anticholinergic drugs suppressed but did not eliminate the adventitious movements. The features of acute dystonic reactions secondary to metoclopramide therapy are reviewed.

    Topics: Acute Disease; Adult; Benztropine; Female; Humans; Metoclopramide; Movement Disorders; Nausea; Time Factors

1984
Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys.
    Psychopharmacology, 1982, Volume: 77, Issue:3

    Various neuroleptic-induced motor disorders that appear in primates previously treated with neuroleptics are collectively designated the acute dyskinetic syndrome. The relative incidence of these motor disorders was examined as the syndrome was repeatedly elicited by haloperidol and other dopamine antagonists in individual monkeys. After several weekly or biweekly treatments with haloperidol (1.25 mg/kg orally), catalepsy began to appear, which was then accompanied by athetoid movements (writhing and limb extensions) as intermittent neuroleptic treatment continued. Other dyskinetic movements ('duck walk', oral dyskinesias, pushing of the head into a cage corner, and perseverative circling) that were suggestive of hyperkinesia subsequently began to be elicited by haloperidol and other neuroleptics after additional treatments with these drugs had intervened. As intermittent treatments continued, tolerance to the athetoid movements gradually developed and, eventually, only circling and pushing could be consistently elicited by haloperidol. In monkeys that had reached this phase, the athetoid movements were not again induced by higher doses of haloperidol (up to 5 mg/kg), chlorpromazine (3 mg/kg), or metoclopramide (3 mg/kg). In these tolerant monkeys, haloperidol impaired Sidman avoidance performance less and benztropine more than in drug-naive monkeys. Neither pharmacokinetic changes nor behavioral tolerance could readily account for these results. It is hypothesized that they reflect progressive functional alterations in dopaminergic or cholinergic neurotransmission.

    Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benztropine; Drug Tolerance; Haloperidol; Male; Movement Disorders; Saimiri

1982
Pharmacology of blepharospasm-oromandibular dystonia syndrome.
    Neurology, 1980, Volume: 30, Issue:7 Pt 1

    Blepharospasm and oromandibular dystonia are clinically similar to other hyperkinetic movement disorders. Dopaminergic antagonist (neuroleptic) and purported cholinergic agonist (deanol) treatment improved symptoms, whereas dopaminergic agonist (carbidopa/levodopa) and cholinergic antagonist (benztropine) drugs worsened symptoms in two patients. This suggested that the syndrome is also pharmacologically related to the hyperkinetic dyskinesias. Symptoms worsened substantially during carbidopa/levodopa but temporarily resolved in one patient and improved in another when the drug was discontinued. This suggests that the pathophysiology of these symptoms involves an idiopathic form of receptor hypersensitivity that can be modified by agonist treatment. The effect of cholinergic agents was less than the effect of dopaminergic drugs, implying that dopamine plays a predominant role in the pathophysiology.

    Topics: Aged; Benztropine; Blepharospasm; Carbidopa; Deanol; Drug Therapy, Combination; Electromyography; Eyelid Diseases; Humans; Jaw Diseases; Levodopa; Male; Middle Aged; Movement Disorders; Syndrome

1980
A middle ground in prophylactic antiparkinsonian medication.
    The American journal of psychiatry, 1977, Volume: 134, Issue:7

    Topics: Antiparkinson Agents; Antipsychotic Agents; Benztropine; Child; Humans; Male; Movement Disorders; Phenothiazines

1977
Neuroleptics and the corpus striatum: clinical implications.
    Diseases of the nervous system, 1976, Volume: 37, Issue:4

    Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloperidol; Humans; Levodopa; Models, Neurological; Movement Disorders; Parkinson Disease; Reserpine; Schizophrenia; Tranquilizing Agents; Trihexyphenidyl

1976
Levodopa-induced myoclonus.
    Archives of neurology, 1975, Volume: 32, Issue:5

    Twelve parkinsonian patients on long-term levodopa therapy developed intermittent, myoclonic body jerks. The movements consisted of single unilateral or bilateral abrupt jerks of the extremities and occurred most frequently during sleep. Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide. Levodopa-induced myoclonus may be related to intermittent increases of activity of serotonin in the brain and results from levodopa-induced dysregulation of serotonin activity.

    Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Levodopa; Male; Methysergide; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Propranolol; Serotonin; Serotonin Antagonists; Sleep; Trihexyphenidyl

1975
Atypical tardive dyskinesia.
    The American journal of psychiatry, 1975, Volume: 132, Issue:5

    The author reports an atypical case of tardive dyskinesia in a 19-year-old male who had been given relatively low dosages of neuroleptic medication for less than 6 months. The symptoms cleared within 3 months after the medication was discontinued. The author reviews the literature regarding similar atypical cases and suggests that increased reporting and careful description of such cases might be useful in furthering our understanding of this syndrome.

    Topics: Adult; Age Factors; Benztropine; Haloperidol; Humans; Male; Movement Disorders; Remission, Spontaneous; Schizophrenia; Time Factors; Tropanes

1975
Letter: Involuntary facial movements.
    British medical journal, 1975, Mar-29, Volume: 1, Issue:5960

    Topics: Benztropine; Female; Humans; Metoclopramide; Movement Disorders

1975
Letter: Potentiation of tardive dyskinesia: possible drug interaction.
    British medical journal, 1975, Apr-19, Volume: 2, Issue:5963

    Topics: Basal Ganglia Diseases; Benztropine; Drug Synergism; Fluphenazine; Humans; Movement Disorders; Tropanes

1975
[Dyskinesia induced by anticholinergic drugs--electrophysiological analysis].
    Rinsho shinkeigaku = Clinical neurology, 1974, Volume: 14, Issue:3

    Topics: Aged; Benztropine; Biperiden; Electromyography; Female; Humans; Male; Middle Aged; Movement Disorders; Parasympatholytics; Parkinson Disease; Phenothiazines; Procyclidine; Trihexyphenidyl

1974
Treatment of phenothiazine drug intoxication with benztropine.
    Archives of disease in childhood, 1974, Volume: 49, Issue:8

    Topics: Antiparkinson Agents; Benztropine; Child; Female; Humans; Infant; Injections, Intravenous; Male; Movement Disorders; Perphenazine; Poisoning; Vomiting

1974
Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome.
    International journal of clinical pharmacology, therapy and toxicology, 1974, Volume: 9, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Benztropine; Diazepam; Female; Humans; Injections, Intravenous; Male; Middle Aged; Movement Disorders; Phenytoin; Tranquilizing Agents; Tryptophan

1974
Antiparkinson drugs as causal agents in tardive dyskinesia.
    The Medical journal of Australia, 1973, Sep-22, Volume: 2, Issue:12

    Topics: Antiparkinson Agents; Antipsychotic Agents; Benztropine; Drug Synergism; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Phenothiazines; Tropanes

1973
Polygraphic profile of oral tardive dyskinesia and of rabbit syndrome: for quantitative and qualitative evaluation.
    Diseases of the nervous system, 1973, Volume: 34, Issue:1

    Topics: Attention; Basal Ganglia Diseases; Benztropine; Diazepam; Electroencephalography; Electromyography; Humans; Lip; Masticatory Muscles; Motor Skills; Movement Disorders; Phenytoin; Sleep; Sleep, REM; Tremor; Tryptophan; Wakefulness

1973
Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
    Psychopharmacologia, 1973, Volume: 29, Issue:4

    Topics: Adult; Basal Ganglia Diseases; Benztropine; Catatonia; Coma; Creatine Kinase; Female; Fever; Fluphenazine; Humans; Movement Disorders; Muscle Rigidity; Phenothiazines; Schizophrenia; Syndrome

1973
[Study of the effect of certain pharmacological agents on tardive dyskinesias and the rabbit syndrome].
    La Vie medicale au Canada francais, 1973, Volume: 2, Issue:9

    Topics: Antiparkinson Agents; Benztropine; Diazepam; Humans; Movement Disorders; Tranquilizing Agents; Tropanes; Tryptophan

1973
The rabbit syndrome. A peculiar extrapyramidal reaction.
    Canadian Psychiatric Association journal, 1972, Volume: 17, Issue:2

    Topics: Aged; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Fatigue; Female; Humans; Male; Masticatory Muscles; Middle Aged; Mouth; Movement Disorders; Perphenazine; Procyclidine; Reserpine; Schizophrenia; Syndrome; Tranquilizing Agents; Trifluoperazine; Trihexyphenidyl

1972
chemdatabank.com